食道癌在治療上, 開刀算是主要治療, 但在不能開刀的病人身上, definitive CCRT 就會是主要的治療, 關於這個主題, 有幾篇經典的論文, 以下就來一一研讀:
1. RTOG8501: T1-3N0-1M0, SCC or adenoCa, 分成兩組, CRT(50Gy/25Fr+5-FU +cisplatin) v.s. RT alone(64Gy/32Fr), 5 yr OS 27%(CRT) v.s. 0%(RT), 10 yr OS, 20%(CRT), SCC 和 adenoCa 在結果上沒差
2. RTOG9405/INT0123: T1-4N0-1M0, SCC or adenoCa, 分成兩組, high dose CCRT(64.8Gy+5-FU +cisplatin) v.s. low dose CCRT(50.4Gy+5-FU +cisplatin), 在interim analysis後, 實驗就終止惹, 在high dose arm 有11個treatment-related death, 兩組在mean survival, 2-year OS, local regional failure沒有統計學上差別
reference:
1. Cooper, Jay S., et al. "Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01)." Jama 281.17 (1999): 1623-1627.
2. Journal of Clinical Oncology 2002 20:5, 1167-1174
3. evidence-based radiation oncology
沒有留言:
張貼留言